Collegium Announces Scientific Presentations at PAINWeek 2018 Meeting
Collegium Pharmaceutical, Inc. (COLL)
Last collegium pharmaceutical, inc. earnings: 2/27 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.collegiumpharma.com
Company Research
Source: GlobeNewswire
STOUGHTON, Mass., Sept. 04, 2018 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that it has supported the following poster presentations on tapentadol (Nucynta® and Nucynta® ER), at PAINWeek 2018 on September 6th in Las Vegas. The following posters will be presented during the poster session on Thursday, September 6th from 6:30 pm - 8:30 pm PT: Poster #39, presented by Dr. Janetta Iwanicki, Scientific Director of Research and Surveillance at Rocky Mountain Poison & Drug Center – Denver Health and Hospital Authority, is titled "Assessment of Tapentadol API Abuse Liability with the Researched Abuse, Diversion and Addiction-Related Surveillance (RADARS®) System Poison Center Program". It compares the rate of intentional abuse of tapentadol active pharmaceutical ingredient (API) to other opioids in the RADARS System Poison Center Program. Poster #40, presented by Dr. Jody Green, Chief Scientific Officer at Inflexxion, an IBH Company, is titled "Nucyn
Show less
Read more
Impact Snapshot
Event Time:
COLL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
COLL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
COLL alerts
High impacting Collegium Pharmaceutical, Inc. news events
Weekly update
A roundup of the hottest topics
COLL
News
- Collegium Pharmaceutical, Inc. Announces Redemption of Outstanding 2.625% Convertible Senior Notes Due 2026 [Yahoo! Finance]Yahoo! Finance
- Collegium Pharmaceutical, Inc. (NASDAQ: COLL) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $40.00 price target on the stock.MarketBeat
- Collegium Pharmaceutical, Inc. Announces Redemption of Outstanding 2.625% Convertible Senior Notes Due 2026GlobeNewswire
- Collegium Pharmaceutical (COLL) Stock Sinks As Market Gains: What You Should Know [Yahoo! Finance]Yahoo! Finance
- Collegium to Participate in 23rd Annual Needham Virtual Healthcare ConferenceGlobeNewswire
COLL
Earnings
- 2/22/24 - Beat
COLL
Sec Filings
- 4/11/24 - Form 8-K
- 4/5/24 - Form ARS
- 4/5/24 - Form DEFA14A
- COLL's page on the SEC website